相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2) : a phase 3, double-blind, randomised, placebo-controlled trial
Eugenio Mercuri et al.
LANCET NEUROLOGY (2022)
Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy
Robert C. Sergott et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
Deepa Chand et al.
JOURNAL OF HEPATOLOGY (2021)
Type I SMA new natural history: long-term data in nusinersen-treated patients
Marika Pane et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series
Deepa H. Chand et al.
JOURNAL OF PEDIATRICS (2021)
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
John W. Day et al.
LANCET NEUROLOGY (2021)
Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go
Tamara Dangouloff et al.
NEUROMUSCULAR DISORDERS (2021)
The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): Results from a US electronic health records study
Emma Viscidi et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
Jerry R. Mendell et al.
JAMA NEUROLOGY (2021)
Advances in the Therapy of Spinal Muscular Atrophy
Jenna Klotz et al.
JOURNAL OF PEDIATRICS (2021)
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
Maria Carmela Pera et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec - A Single Centre Experience
Johannes Friese et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2021)
European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
Janbernd Kirschner et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2020)
From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1
Samiah A. Al-Zaidy et al.
PEDIATRIC NEUROLOGY (2019)
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Darryl C. De Vivo et al.
NEUROMUSCULAR DISORDERS (2019)
Intrathecal administration of onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 2 (SMA2): phase 1/2a study (STRONG)
R. Finkel et al.
NEUROMUSCULAR DISORDERS (2019)
Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
Eugenio Mercuri et al.
NEUROMUSCULAR DISORDERS (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy
Kevin A. Strauss et al.
JOURNAL OF PEDIATRIC ORTHOPAEDICS (2018)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Disease Mechanisms and Therapeutic Approaches in Spinal Muscular Atrophy
Sarah Tisdale et al.
JOURNAL OF NEUROSCIENCE (2015)
Observational study of spinal muscular atrophy type I and implications for clinical trials
Richard S. Finkel et al.
NEUROLOGY (2014)
Natural history of denervation in SMA:: Relation to age, SMN2 copy number, and function
KJ Swoboda et al.
ANNALS OF NEUROLOGY (2005)